About Bosutinib (CAS 380843-75-4), also known as PF-05208763 and often referred to in research as bosutinib pfizer, is a potent tyrosine kinase inhibitor targeting BCR-ABL and Src family kinases. These kinases play a critical role in cellular signaling pathways that regulate proliferation, survival, and differentiation. Because abnormal activation of these pathways is associated with several types of leukemia, Bosutinib has become an important compound in oncology and kinase signaling research.
The compound has a well-defined molecular formula and physicochemical properties suitable for experimental work in biochemical and pharmacological models. Researchers frequently buy 380843-75-4 to study mechanisms of tyrosine kinase inhibition and to evaluate signaling pathways involved in tumor development. Due to its well-characterized activity profile, Bosutinib is widely used in pharmaceutical and academic laboratories investigating targeted cancer therapies.
Application of Bosutinib
Bosutinib is widely applied in research related to cancer biology and kinase signaling. By inhibiting BCR-ABL and Src kinases, the compound helps scientists investigate the molecular mechanisms that drive tumor growth and resistance to therapy.
- Research on BCR-ABL signaling pathways
- Development of targeted leukemia therapies
- Screening and validation of kinase inhibitors
- Studies of oncogenic signaling and drug resistance
Researchers often buy Bosutinib as a reference compound for evaluating the activity of newly developed kinase inhibitors.
In Vitro
In vitro experiments show that Bosutinib effectively inhibits BCR-ABL kinase activity in cultured leukemia cell lines. This inhibition disrupts downstream signaling pathways such as MAPK and PI3K/AKT, which are involved in cell proliferation and survival. As a result, Bosutinib suppresses tumor cell growth and helps researchers investigate mechanisms of kinase-driven oncogenesis.
In Vivo
In vivo studies demonstrate that Bosutinib can reduce tumor growth in preclinical models by blocking oncogenic kinase signaling. These studies provide insight into how inhibition of BCR-ABL and Src kinases influences disease progression and treatment response in leukemia and related malignancies.
Biochemical and Physiological Actions
The biochemical activity of Bosutinib involves selective inhibition of multiple tyrosine kinases, including BCR-ABL and members of the Src kinase family. By preventing phosphorylation of downstream substrates, the compound interferes with signaling pathways responsible for uncontrolled cell proliferation and survival.
Features and Benefits of Bosutinib
- Potent inhibitor of BCR-ABL and Src family kinases
- Important tool for studying leukemia-related signaling pathways
- Suitable for in vitro and in vivo experimental models
- Reliable reference compound for kinase inhibitor research
High-quality bioactive compounds are essential for modern biomedical research. Scientists working in pharmaceutical, biotechnology, and academic laboratories rely on validated molecules to investigate disease mechanisms, accelerate drug discovery programs, and support the development of targeted therapeutic strategies.
